First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    argenx SE

    ARGX · 4 developments mapped · last assessed 2026-08-27

    Market Ontology has mapped 4 macro, policy, and market developments to argenx SE since 2026-08-19. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for ARGX yet, so no modelled value is shown. The ARGX valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run ARGX on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for ARGX. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Open question

      argenx BV Completes Acquisition of Forte Biosciences, Inc. via Tender Offer

      Direct acquisition of a company, impacting financial statements and strategic direction. Integration risks and potential synergies will unfold over time.

      · Moves future growth rates, synergy realization, integration costs

    What changed, by assumption

    Future growth rates
    • 2026-08-27argenx BV Completes Acquisition of Forte Biosciences, Inc. via Tender Offer
    Future growth rates (synergies, pipeline expansion)
    • 2026-08-27argenx Completes Acquisition of Forte Biosciences, Inc.
    Future growth rates (revenue, earnings)
    • 2026-08-19argenx SE satisfies HSR clearance for acquisition of Forte Biosciences, Inc.
    Future growth rates (revenue)
    • 2026-08-19argenx SE to acquire Forte Biosciences, Inc. for $77.00 per share in cash

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-06Net debtBearishLiability-management transactions often reduce gross debt or push maturities out.0.70
    2026-08-06Interest expenseBearishTender/exchange extends maturity profile and typically lowers near-term interest expense.0.70
    2026-07-27Share countBullishStock component of consideration dilutes existing acquirer holders.0.70
    2026-07-27Net debtBullishCash component of consideration is typically debt-funded, raising net debt.0.70
    2026-07-27RevenueBullishAcquisition adds target revenue to acquirer P&L on close.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-08-27argenx BV Completes Acquisition of Forte Biosciences, Inc. via Tender Offermixed3-12m0.60
    2026-08-27argenx Completes Acquisition of Forte Biosciences, Inc.mixed3-12m0.60
    2026-08-19argenx SE satisfies HSR clearance for acquisition of Forte Biosciences, Inc.mixed1-5y0.60
    2026-08-19argenx SE to acquire Forte Biosciences, Inc. for $77.00 per share in cashmixed1-5y0.60